LENZ Therapeutics, Inc. (LENZ): Cash & Equivalents
$25.18M
As of 2025-12-31
$24.21M
As of 2026-06-30
-19.2%
3-year compound annual growth
+4.9%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $25.18M | +24.9% | 2026-03-24, Balance as of period end |
| 2024-12-31 | $20.16M | -42.6% | 2026-03-24, Balance as of period end |
| 2023-12-31 | $35.14M | -26.4% | 2025-03-19, Balance as of period end |
| 2022-12-31 | $47.73M | -87.3% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $376.98M | n/m | 2023-03-20, Balance as of period end |
| 2020-12-31 | $19.78M | n/a | 2022-03-21, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $25.18M | +24.9% |
| Alector, Inc. (ALEC) | 2025-12-31 | $65.80M | +99.3% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $17.97M | n/m |
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $84.02M | -32.4% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $40.79M | -10.9% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $41.72M | +52.3% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $4.96M | +51.4% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $12.36M | -24.1% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $110.82M | +29.0% |
Compare LENZ, ALEC, PTHS, RLAY side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗